Inhibin and the regulation of bone mass

被引：13

作者：

Gaddy D. ^{[1
]}

机构：

[1] Department of Physiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205

来源：

Current Osteoporosis Reports | 2008年 / 6卷 / 2期

关键词：

Bone Turnover; Activin; Osteoclast Differentiation; Inhibin; Distraction Osteogenesis;

D O I：

10.1007/s11914-008-0009-5

中图分类号：

学科分类号：

摘要：

Inhibins A and B are gonadal peptide members of the transforming growth factor-β superfamily that serve as negative feedback regulators of pituitary follicle-stimulating hormone (FSH). Accumulating evidence suggests that bone turnover and bone loss increase in women before menopause and the decrease in serum estradiol levels. Increased FSH levels have been correlated with some of these perimenopausal changes, whereas decreased inhibins strongly correlate with increases in bone formation and resorption across the menopause transition, and predict lumbar bone mass in perimenopausal women, likely resulting from the direct inhibin suppression of osteoblast and osteoclast development. Interestingly, continuous exposure of mice to inhibin A in vivo is anabolic and protective against gonadectomy-induced bone loss. Together, these data suggest inhibins contribute to the endocrine regulation of bone metabolism via a bimodal mechanism of action such that cycling inhibin exposure suppresses bone turnover, and continuous exposure to inhibins is anabolic. © Springer Science+Business Media, LLC 2008.

引用

页码：51 / 56

页数：5

共 45 条

[1]

Albright F., Bloomberg E., Smith P.H., Postmenopausal osteoporosis, Trans Assoc Am Physicians, 55, pp. 298-305, (1940)

[2]

Manolagas S.C., Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis, Endocr Rev, 21, pp. 115-137, (2000)

[3]

Martin T.J., Sims N.A., Osteoclast-derived activity in the coupling of bone formation to resorption, Trends Mol Med, 11, pp. 76-81, (2005)

[4]

Manolagas S.C., Kousteni S., Jilka R.L., Sex steroids and bone, Recent Prog Horm Res, 57, pp. 385-409, (2002)

[5]

Riggs B.L., Endocrine causes of age-related bone loss and osteoporosis, Novartis Found Symp, 242, pp. 247-259, (2002)

[6]

Khosla S., Atkinson E.J., Melton III L.J., Riggs B.L., Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: A population-based study, J Clin Endocrinol Metab, 82, pp. 1522-1527, (1997)

[7]

Khosla S., Melton III L.J., Atkinson E.J., Et al., Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen, J Clin Endocrinol Metab, 83, pp. 2266-2274, (1998)

[8]

Riggs B.L., Khosla S., Melton III L.J., Primary osteoporosis in men: Role of sex steroid deficiency, Mayo Clin Proc, 75, SUPPL., (2000)

[9]

Ebeling P.R., Atley L.M., Guthrie J.R., Et al., Bone turnover markers and bone density across the menopausal transition, J Clin Endocrinol Metab, 81, pp. 3366-3371, (1996)

[10]

Riggs B.L., Melton III L.J., Robb R.A., Et al., Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites, J Bone Miner Res, 19, pp. 1945-1954, (2004)

← 1 2 3 4 5 →